BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

The Oncologic Drugs Advisory Committee (ODAC ... the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...

Kanvas Bio Unveils Clinical Data on the Gut Microbiome’s Impact on Anti-Tumoral Immunity at SITC ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...

Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...

HUYABIO International today announced it will present the final analysis of data from a phase 2 study evaluating HBI-8000 in combination with nivolumab (anti-PD1 therapy), a novel combination for the ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...